Interview

CUREator, the biotech incubator operated by Brandon BioCatalyst, has awarded $1.23 million in top-up funding to six early-stage projects that have outperformed expectations in its Preclinical and Minimising Antimicrobial Resistance streams.

A team of Australian and Japanese scientists has uncovered a protein particle within the SARS-CoV-2 virus that could form the basis of more durable and protective COVID-19 vaccines.

Cell therapy company Mesoblast (ASX:MSB) has struck a deal with two major investors that could deliver up to US$50 million (A$76.8 million) in new funding, strengthening its balance sheet and supporting its clinical pipeline.

Amplia Therapeutics (ASX:ATX) has dosed the first patient in its new pancreatic cancer trial, marking the official start of a study testing its lead FAK inhibitor narmafotinib (AMP945) in combination with chemotherapy.

AusBiotech has appointed Hayley van der Meer as its new Director of Membership Services and Strategic Partnerships, a move the organisation describes as pivotal for both its future and the broader life sciences sector.

AusBiotech CEO Rebekah Cassidy said, “For our sector to thrive, it needs a coordinated and well-invested research sector. Without research, there is no pipeline of health innovation, no pipeline of companies, and no ecosystem to sustain them.”

Immuron (ASX:IMC) has closed the financial year 2025 with record sales and significant progress across its clinical programs, positioning the company for another pivotal year ahead.

Island Pharmaceuticals (ASX:ILA) has declared the financial year 2025 as defining, having delivered encouraging trial results for its dengue program and acquired a second antiviral asset, which positions the company as a dual-asset player in global infectious diseases.

Prescient Therapeutics (ASX:PTX) has secured fresh backing from investors, completing a $3 million capital raise to support the clinical development of its targeted cancer therapy PTX-100.

OncoSil Medical (ASX:OSL) has capped a significant year with major regulatory approvals, clinical trial progress, and expanding commercial traction for its brachytherapy device in pancreatic cancer.

Neurotech International (ASX: NTI) has reported a year of significant clinical achievements, regulatory recognition, and corporate renewal as it advances its proprietary cannabinoid therapy, NTI164, for paediatric neurological disorders.

Paradigm Biopharmaceuticals (ASX:PAR) has marked 2025 as a transformative year, moving from regulatory preparation to the active execution of its global Phase 3 clinical trial for iPPS (Zilosul) in knee osteoarthritis, while also strengthening its financial foundations and broadening its treatment pipeline.